Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

被引：0

作者：

Wang, Michael ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Trneny, Marek ^{[3
]}

Belada, David ^{[4
]}

Wrobel, Tomasz ^{[5
]}

Ghosh, Nilanjan ^{[6
]}

Keating, Mary-Margaret ^{[7
]}

van Meerten, Tom ^{[8
]}

Alvarez, Ruben Fernandez ^{[9
]}

von Keudell, Gottfried ^{[10
]}

Thieblemont, Catherine ^{[11
]}

Peyrade, Frederic ^{[12
]}

Andre, Marc

Hoffmann, Marc ^{[13
,14
]}

Glusman, Edith Szafer ^{[15
]}

Lin, Jennifer ^{[15
]}

Dean, James P. ^{[15
]}

Neuenburg, Jutta K. ^{[15
]}

Tam, Constantine S. ^{[16
,17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[3] Gen Univ Hosp Prague, Prague, Czech Republic

[4] Charles Univ Prague, Hosp & Fac Med, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic

[5] Wroclaw Med Univ, Wroclaw, Poland

[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Univ Med Ctr Groningen, Groningen, Netherlands

[9] Hosp Univ Cabuenes, Asturias, Spain

[10] Beth Israel Deaconess Med Ctr, Boston, MA USA

[11] Univ Paris, Hop St Louis, Assistance Publ Hop Paris, Serv Hematoncol, Paris, France

[12] Ctr Antoine Lacassagne, Nice, France

[13] CHU UCL Namur Mont Godinne, Yvoir, Belgium

[14] Univ Kansas, Ctr Canc, Kansas City, KS USA

[15] AbbVie, N Chicago, IL USA

[16] Alfred Hlth, Peter MacCallum Canc Ctr, Melbourne, Australia

[17] Monash Univ, Melbourne, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
Wang, Michael
Jurczak, Wojciech
Trneny, Marek
Belada, David
Wrobel, Tomasz
Ghosh, Nilanjan
Keating, Mary-Margaret
van Meerten, Tom
Fernandez Alvarez, Ruben
von Keudell, Gottfried
Thieblemont, Catherine
Peyrade, Frederic
Andre, Marc
Hoffmann, Marc
Glusman, Edith Szafer
Lin, Jennifer
Dean, James P.
Neuenburg, Jutta K.
Tam, Constantine S.
BLOOD, 2024, 144 : LBA5 - LBA5
[2] Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study
Tam, Constantine S.
Ramchandren, Radhakrishnan
Chen, Robert
Karlin, Lionel
Chong, Geoffrey
Jurczak, Wojciech
Wu, Ka Lung
Bishton, Mark
Collins, Graham P.
Eliadis, Paul
Peyrade, Frederic
Szafer-Glusman, Edith
Lee, Yihua
Eckert, Karl
Neuenburg, Jutta K.
Wang, Michael
BLOOD, 2020, 136
[3] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Wang, Michael
Ramchandren, Radhakrishnan
Chen, Robert
Karlin, Lionel
Chong, Geoffrey
Jurczak, Wojciech
Wu, Ka Lung
Bishton, Mark
Collins, Graham P.
Eliadis, Paul
Peyrade, Frederic
Lee, Yihua
Eckert, Karl
Neuenburg, Jutta K.
Tam, Constantine S.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[4] Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael Wang
Radhakrishnan Ramchandren
Robert Chen
Lionel Karlin
Geoffrey Chong
Wojciech Jurczak
Ka Lung Wu
Mark Bishton
Graham P. Collins
Paul Eliadis
Frédéric Peyrade
Yihua Lee
Karl Eckert
Jutta K. Neuenburg
Constantine S. Tam
Journal of Hematology & Oncology, 14
[5] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Goto, Hideki
Ito, Satoshi
Kizaki, Masahiro
Yamaguchi, Masaki
Fukuhara, Noriko
Kato, Koji
Saito, Toko
Terui, Yasuhito
Okubo, Sumiko
Soshin, Tomomi
Zeng, Jiewei
Honda, Hideyuki
Badawi, Mohamed
Ross, Jeremy A.
Izutsu, Koji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
[6] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Izutsu, Koji
Goto, Hideki
Kizaki, Masahiro
Yamaguchi, Masaki
Fukuhara, Noriko
Kato, Koji
Saito, Toko
Terui, Yasuhito
Okubo, Sumiko
Soshin, Tomomi
Mukherjee, Nabanita
Honda, Hideyuki
Badawi, Mohamed
Ross, Jeremy
Ishizawa, Kenichi
ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
[7] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Hideki Goto
Satoshi Ito
Masahiro Kizaki
Masaki Yamaguchi
Noriko Fukuhara
Koji Kato
Toko Saito
Yasuhito Terui
Sumiko Okubo
Tomomi Soshin
Jiewei Zeng
Hideyuki Honda
Mohamed Badawi
Jeremy A. Ross
Koji Izutsu
International Journal of Clinical Oncology, 2024, 29 : 232 - 240
[8] Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Wang, Michael
Jurczak, Wojciech
Trneny, Marek
Belada, David
Wrobel, Tomasz
Ghosh, Nilanjan
Keating, Mary-Margaret
van Meerten, Tom
Alvarez, Ruben Fernandez
von Keudell, Gottfried
Thieblemont, Catherine
Peyrade, Frederic
Andre, Marc
Hoffmann, Marc
Szafer-Glusman, Edith
Lin, Jennifer
Dean, James P.
Neuenburg, Jutta K.
Tam, Constantine S.
LANCET ONCOLOGY, 2025, 26 (02): : 200 - 213
[9] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
Grieve, Clare
Joseph, Ashlee
Drullinsky, Pamela
Zelenetz, Andrew D.
Hamlin, Paul
Kumar, Anita
LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
[10] Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
Portell, Craig A.
Wages, Nolan A.
Kahl, Brad S.
Budde, Lihua E.
Chen, Robert W.
Cohen, Jonathon B.
Varhegyi, Nikole E.
Petroni, Gina R.
Williams, Michael E.
BLOOD ADVANCES, 2022, 6 (05) : 1490 - 1498

← 1 2 3 4 5 →